Charles River Laboratories International, Inc. $CRL Shares Acquired by Zions Bancorporation National Association UT

Zions Bancorporation National Association UT lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,522 shares of the medical research company’s stock after purchasing an additional 969 shares during the period. Zions Bancorporation National Association UT’s holdings in Charles River Laboratories International were worth $1,748,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Brooklyn Investment Group grew its holdings in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after buying an additional 86 shares during the last quarter. Cromwell Holdings LLC boosted its stake in shares of Charles River Laboratories International by 542.9% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 152 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Charles River Laboratories International during the 2nd quarter worth about $56,000. Bayforest Capital Ltd acquired a new position in Charles River Laboratories International in the 2nd quarter valued at about $63,000. Finally, Family Legacy Financial Solutions LLC acquired a new position in Charles River Laboratories International in the 2nd quarter valued at about $71,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.7%

CRL stock opened at $167.99 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The company has a market cap of $8.27 billion, a price-to-earnings ratio of -126.31, a PEG ratio of 4.83 and a beta of 1.53. The business has a fifty day simple moving average of $168.00 and a 200-day simple moving average of $155.67. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $222.10.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.59 earnings per share. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity

In related news, EVP Joseph W. Laplume sold 800 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares of the company’s stock, valued at approximately $3,800,681.60. This represents a 3.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CRL shares. William Blair upgraded shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Mizuho boosted their price target on Charles River Laboratories International from $155.00 to $174.00 and gave the company a “neutral” rating in a report on Friday, October 17th. Baird R W raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and upped their target price for the company from $142.00 to $195.00 in a research note on Tuesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $186.93.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).